STANTON PARK GROUP

Lobbying for KYOWA KIRIN · Pharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Pharmacy

FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to Newborn Screening and Genetic Testing;

Trade (domestic/foreign)

Issues Related to Trade

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.